Infarction with associated pseudosarcomatous changes mimics anaplasia in otherwise grade I meningiomas

Tejus A Bale1, Jamal Benhamida2, Sudarshana Roychoudury2

  • 1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. balet@mskcc.org.

Insights

Pseudosarcomatous changes in WHO grade I meningiomas are reactive to tumor infarction, not anaplasia. These indolent tumors show no recurrence, unlike higher-grade meningiomas, and are identifiable via DNA methylation analysis.

Area of Science:

  • Neuropathology
  • Oncology
  • Molecular Diagnostics

Background:

  • WHO grade I meningiomas are typically benign tumors.
  • Tumor infarction can occur in meningiomas, potentially mimicking higher-grade features.
  • Distinguishing reactive changes from true anaplasia is crucial for accurate prognosis.

Purpose of the Study:

  • To characterize a distinct pattern of tumor infarction and sarcoma-like changes in WHO grade I meningiomas.
  • To differentiate these pseudosarcomatous changes from actual anaplastic features.
  • To evaluate the utility of DNA methylation profiling in classifying these meningiomas.

Main Methods:

  • Histopathological analysis of 9 WHO grade I meningiomas with pseudosarcomatous changes.
  • Comparison with 16 WHO grade II and III meningiomas.
  • Immunohistochemistry for PR, SSTR2A, EMA, and SMA.
  • DNA methylation-based analysis using the meningioma v2.4 classifier.

Main Results:

  • WHO grade I meningiomas with infarction showed a pseudosarcomatous component, brisk mitotic activity, and high Ki-67, but no recurrence.
  • Higher-grade meningiomas (WHO II/III) exhibited high progression rates and multiple chromosomal losses.
  • DNA methylation analysis classified pseudosarcomatous cases as "MC benign-1" with isolated 22q loss, distinct from higher-grade tumors.

Conclusions:

  • Pseudosarcomatous changes in meningiomas are likely reactive to infarction, not indicative of anaplasia.
  • These specific WHO grade I meningiomas are indolent and should be distinguished from aggressive subtypes.
  • DNA methylation profiling is a valuable tool for accurate meningioma classification and behavior prediction.